Evidence map›Paper›PMID 40286790›Full record

ArticleImmunity2025

Nerve- and airway-associated interstitial macrophages mitigate SARS-CoV-2 pathogenesis via type I interferon signaling.

Stephen T Yeung, Payal Damani-Yokota, Sara A Thannickal, Eric Bartnicki, Eduardo D Bernier, Clea R Barnett, Camille Khairallah, Ralf Duerr, Maria G Noval, Leopoldo N Segal and 2 more

Abstract read
In one paragraph

Article in Immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Macrophages: sentinels, warriors, and healers.Human molecular genetics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stephen T YeungDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Payal Damani-YokotaDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Sara A ThannickalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Eric BartnickiDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Eduardo D BernierDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Clea R BarnettDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.
Camille KhairallahDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Ralf DuerrDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA; Department of Medicine, Vaccine Center, New York University Grossman School of Medicine, New York, NY 10016, USA.
Maria G NovalDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Leopoldo N SegalLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA; Department of Medicine, Division of Pulmonary and Critical Care Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.
Kenneth A StaplefordDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Kamal M KhannaDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: kamal.khanna@nyulangone.org.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancerR37CA244775 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Leopoldo Nicolas Segal · 2020 to 2026
$4.7M
Novel lung resident interstitial macrophage subset with distinct localization and polarizationR01AI143861 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KHANNA, KAMAL MOHAN · 2019 to 2023
$3.3M
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1R01AI162774 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Kenneth Stapleford · 2022 to 2026
$2.7M
UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
Effect of obesity and diabetes in regulating pulmonary and extra-pulmonary anti-viral immune responsesR01DK138675 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Kamal Mohan Khanna, ANN MARIE SCHMIDT · 2024 to 2026
$2.3M
Role of resident macrophages in type II responses and trained immunityR01AI188824 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Kamal Mohan Khanna · 2025 to 2026
$1.7M
Age related loss of immune resilience during response to severe respiratory viral infectionsU01AG088351 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHRISTIAN FORST, Leopoldo Nicolas Segal · 2024 to 2026
$1.5M
BIOREPOSITORY OPTIMIZATION AND USE FOR ENDOTYPING CRITICALLY ILL SARS-COV-2 INFECTED PATIENTSR33GM147800 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGAL, LEOPOLDO NICOLAS · 2024 to 2025
$1.5M
Lung resident macrophage subsets in regulating tissue immunity - Resubmission - 1F32HL154598 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAMANI-YOKOTA, PAYAL · 2021 to 2022
$85k
NCI NIH HHS P30 CA016087NCI NIH HHS R37 CA244775NHLBI NIH HHS F32 HL154598NIAID NIH HHS R01 AI143861NIAID NIH HHS R01 AI162774NIAID NIH HHS R01 AI188824NIAID NIH HHS R25 AI147376NIA NIH HHS U01 AG088351NIDDK NIH HHS R01 DK138675NIGMS NIH HHS R33 GM147800
6 · The paper itself

Abstract

Despite vaccines, rapidly mutating viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to threaten human health due to an impaired immunoregulatory pathway and a hyperactive immune response. Our understanding of the local immune mechanisms used by tissue-resident macrophages to safeguard the host from excessive inflammation during SARS-CoV-2 infection remains limited. Here, we found that nerve- and airway-associated interstitial macrophages (NAMs) are required to control mouse-adapted SARS-CoV-2 (MA-10) infection. Control mice restricted lung viral distribution and survived infection, whereas NAM depletion enhanced viral spread and inflammation and led to 100% mortality. Mechanistically, type I interferon receptor (IFNAR) signaling by NAMs was critical for limiting inflammation and viral spread, and IFNAR deficiency in CD169

Indexed as

COVID-19Interferon Type IMacrophagesSARS-CoV-2AnimalsHumansLungMiceMice, Inbred C57BLMice, KnockoutReceptor, Interferon alpha-betaSialic Acid Binding Ig-like Lectin 1Signal TransductionIfnar1 protein, mouseInterferon Type IReceptor, Interferon alpha-betaSialic Acid Binding Ig-like Lectin 1CD169disease toleranceimmunoregulationimmunosuppressioninnate immunityinterferonsMA-10nerve- and airway-associated interstitial macrophagesSARS-CoV-2Siglec-1tissue-resident macrophages

Identifiers

PMID40286790
PMCPMC12096317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.